



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:

Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:

03.06.2015 Bulletin 2015/23

(45) Date of publication and mention
of the grant of the patent:

29.04.2015 Bulletin 2015/18

(21) Application number: **10807186.1**

(22) Date of filing: **05.08.2010**

(51) Int Cl.:

C07C 229/48 ^(2006.01)	C07C 237/08 ^(2006.01)
C07C 237/52 ^(2006.01)	C07C 309/14 ^(2006.01)
C07C 311/51 ^(2006.01)	C07D 205/04 ^(2006.01)
C07D 207/16 ^(2006.01)	C07D 209/08 ^(2006.01)
C07D 211/60 ^(2006.01)	C07D 211/62 ^(2006.01)
C07D 215/20 ^(2006.01)	C07D 217/24 ^(2006.01)
C07D 257/04 ^(2006.01)	C07D 305/08 ^(2006.01)
C07D 403/06 ^(2006.01)	C07D 417/06 ^(2006.01)
A61P 3/10 ^(2006.01)	A61P 29/00 ^(2006.01)
A61P 35/00 ^(2006.01)	A61P 11/06 ^(2006.01)

(86) International application number:

PCT/US2010/044607

(87) International publication number:

WO 2011/017561 (10.02.2011 Gazette 2011/06)

(54) **BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS**

BIZYKLISCHE ARYL-SPHINGOSIN-1-PHOSPHAT-ANALOGUE

ANALOGUES D'ARYLSPHINGOSINE-1-PHOSPHATE BICYCLIQUES

(84) Designated Contracting States:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO SE SI SK SM TR

Designated Extension States:

BA ME RS

(30) Priority: **05.08.2009 US 231539 P**

(43) Date of publication of application:

13.06.2012 Bulletin 2012/24

(60) Divisional application:

15165518.0

(73) Proprietor: **Biogen MA Inc.**

Cambridge, MA 02142 (US)

(72) Inventors:

- **THOMAS, Jermaine**
Chelsea
MA 02150 (US)
- **LIU, Xiaogao**
Dover
MA 02030 (US)

- **LIN, Edward, Yin-Shiang**

Chestnut Hill
MA 02467 (US)

- **ZHENG, Guo, Zhu**

Lexington
MA 02420 (US)

- **MA, Bin**

Arlington
MA 02474 (US)

- **CALDWELL, Richard, D.**

Somerville
MA 02144 (US)

- **GUCKIAN, Kevin, M.**

Marlborough
MA 01752 (US)

- **KUMARAVEL, Gnanasambandam**

Westford
MA 01886 (US)

- **TAVERAS, Arthur, G.**

Southborough
MA 01772 (US)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

(74) Representative: **Miller, David James et al**
Mathys & Squire LLP
The Shard
32 London Bridge Street
London SE1 9SG (GB)

(56) References cited:

WO-A1-2006/080477 WO-A1-2007/092638
WO-A1-2009/023854 WO-A1-2010/051030
WO-A1-2010/051031 US-A1- 2004 254 215
US-A1- 2008 027 036 US-A1- 2009 131 400

- **CHRISTINA N. CARRIGAN ET AL: "Synthesis and in Vitro Pharmacology of Substituted Quinoline-2,4-dicarboxylic Acids as Inhibitors of Vesicular Glutamate Transport", JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 11, 1 May 2002 (2002-05-01), pages 2260-2276, XP55040588, ISSN: 0022-2623, DOI: 10.1021/jm010261z**

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification